Follow
Alice Mims
Alice Mims
Assistant Professor of Internal Medicine/Hematology, The Ohio State University
Verified email at osumc.edu
Title
Cited by
Cited by
Year
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ...
New England Journal of Medicine 378 (25), 2386-2398, 2018
13842018
Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology
MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ...
Journal of the National Comprehensive Cancer Network 17 (6), 721-749, 2019
4302019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ...
Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020
3342020
NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines
DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ...
Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021
2392021
Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia
X Huang, S Schwind, B Yu, R Santhanam, H Wang, P Hoellerbauer, ...
Clinical Cancer Research 19 (9), 2355-2367, 2013
2122013
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ...
Blood, The Journal of the American Society of Hematology 137 (13), 1792-1803, 2021
1722021
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ...
Blood advances 4 (9), 1894-1905, 2020
1492020
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
J Aimiuwu, H Wang, P Chen, Z Xie, J Wang, S Liu, R Klisovic, A Mims, ...
Blood, The Journal of the American Society of Hematology 119 (22), 5229-5238, 2012
1482012
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ...
Nature medicine 26 (12), 1852-1858, 2020
1302020
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged< 60 years
AK Eisfeld, J Kohlschmidt, A Mims, D Nicolet, CJ Walker, JS Blachly, ...
Leukemia 34 (12), 3215-3227, 2020
882020
Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads†…
EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ...
Blood 132, 560, 2018
802018
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response†…
TL Lasho, A Mims, MA Elliott, C Finke, A Pardanani, A Tefferi
Leukemia 28 (6), 1363-1365, 2014
732014
Incidence and survival of hematological cancers among adults ages≥ 75 years
JL Krok‐Schoen, JL Fisher, JA Stephens, A Mims, S Ayyappan, ...
Cancer medicine 7 (7), 3425-3433, 2018
712018
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling
B Cen, Y Xiong, JH Song, S Mahajan, R DuPont, K McEachern, ...
Molecular and cellular biology, 2014
712014
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
A Mims, AR Walker, X Huang, J Sun, H Wang, R Santhanam, ...
Leukemia 27 (4), 871-878, 2013
692013
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome
AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ...
Blood Advances 4 (19), 4648-4652, 2020
682020
Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific†…
F Ravandi, A Bashey, W Stock, JM Foran, R Mawad, D Egan, W Blum, ...
Blood 136, 4-5, 2020
632020
Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD
SA Wall, Q Zhao, M Yearsley, L Blower, A Agyeman, P Ranganathan, ...
Blood advances 2 (20), 2619-2628, 2018
562018
Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia
B Bhatnagar, J Kohlschmidt, K Mrůzek, Q Zhao, JL Fisher, D Nicolet, ...
Cancer discovery 11 (3), 626-637, 2021
522021
Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody†…
F Ravandi, A Bashey, JM Foran, W Stock, R Mawad, W Blum, MW Saville, ...
Blood 132, 763, 2018
522018
The system can't perform the operation now. Try again later.
Articles 1–20